Search

Jennifer R Grandis

from San Francisco, CA
Age ~63
Get Report
Also known as:
Jennifer Rubin Grandis, Jennifer Rubi Grandis, Jennifer J Grandis, Jennifer R Rubin
Phone and address:
2025 Lake St, San Francisco, CA 94121
(412) 310-2876
Related to:
Kathy J Rubin, 72Benjamin R Grandis, 31Simone S Rubin, 63Anna R GrandisDonald J Grandis, 64Benjamin R GrandisDaniel A Rubin, 64Anna Grandis, 29Daniela Rubin
Connected to:
Audrey L Grandison, 86Audricka T Grandison, 61Bryana J Grandison, 31Chiquira Grandison, 45Clement Grandison, 33Cyan T Grandison, 32Deborah A Grandison, 65Dian P Grandison, 54Eldora N Grandison, 42Gwendolyn Grandison, 68

Jennifer Grandis Phones & Addresses

  • 2025 Lake St, San Francisco, CA 94121 (412) 310-2876
  • Sanibel, FL
  • 525 Edgerton Ave, Pittsburgh, PA 15208 (412) 661-0870
  • 95 Woodland Ave, Pittsburgh, PA 15232 (412) 661-0870
  • Lee, FL

Work

Company: Univ Pittsbrg Phys ENT Specs Address: 203 Lothrop St Suite 300, Pittsburgh, PA 15213 Phones: (412) 647-2100

Education

School / High School: University of Pittsburgh / Main Campus 1987

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Otolaryngology, 1994

Specialities

Ear, Nose, and Throat

Professional Records

Medicine Doctors

Jennifer Grandis Photo 1

Dr. Jennifer R Grandis, Pittsburgh PA - MD (Doctor of Medicine)

View page
Specialties:
Ear, Nose, and Throat
Address:
Univ Pittsbrg Phys ENT Specs
203 Lothrop St Suite 300, Pittsburgh, PA 15213
(412) 647-2100 (Phone)
Certifications:
Otolaryngology, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Univ Pittsbrg Phys ENT Specs
203 Lothrop St Suite 300, Pittsburgh, PA 15213

Upmc Mercy
1400 Locust Street, Pittsburgh, PA 15219

Upmc Presbyterian Shadyside
200 Lothrop Street, Pittsburgh, PA 15213

Upmc Shadyside
5230 Centre Avenue, Pittsburgh, PA 15232
Education:
Medical School
University of Pittsburgh / Main Campus
Graduated: 1987
Medical School
University Of Pittsburgh
Graduated: 1987
Jennifer Grandis Photo 2

Jennifer Rubin Grandis, Pittsburgh PA

View page
Specialties:
Otolaryngology
Plastic Surgery within the Head & Neck
Surgery
Plastic Surgery Within the Head and Neck
Work:
University of Pittsburgh
200 Lothrop St, Pittsburgh, PA 15213
Education:
University of Pittsburgh(1987)

License Records

Jennifer Grandis

License #:
MT019077T - Expired
Category:
Medicine
Type:
Graduate Medical Trainee

Jennifer Rubin Grandis

Address:
Pittsburgh, PA 15232
License #:
MD044455E - Expired
Category:
Medicine
Type:
Medical Physician and Surgeon

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jennifer Grandis
Otolaryngology
University of Pittsburgh Physicians
General Hospital Health Practitioner's Office · Health Practitioner's Office
203 Lothrop St, Pittsburgh, PA 15213
(412) 647-2030
Jennifer Rubin Grandis
Grandis, Dr. Jennifer R
Ent
200 Lothrop St, Pittsburgh, PA 15213
(412) 647-2100

Publications

Wikipedia References

Jennifer Grandis Photo 3

Jennifer Grandis

Us Patents

Inhibition Of Human Squamous Cell Carcinoma Growth In Vivo By Epidermal Growth Factor Receptor Antisense Rna Transcribed From A Pol Iii Promoter

View page
US Patent:
7662793, Feb 16, 2010
Filed:
Mar 12, 2003
Appl. No.:
10/387252
Inventors:
Yukai He - Pittsburgh PA, US
Jennifer R. Grandis - Pittsburgh PA, US
Leaf Huang - Pittsburgh PA, US
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
C07H 21/02
C07H 21/04
A61K 31/70
A01N 43/04
US Classification:
514 44, 536 231, 536 243, 536 2433, 536 245
Abstract:
A nucleic acid is provided comprising an expression cassette which includes transcription control sequences of a member of a class of Pol III-transcribed genes in which no transcribed portion of the Pol III gene is required for transcription of the gene. In the expression cassette, the transcribed 5′ hairpin structure of the Pol III gene is deleted. The transcription control sequences are operably linked to a sequence of an EGFR gene in an antisense orientation suitable for decreasing expression of EGFR in the cell when transcribed. Lastly, a method for decreasing expression of EGFR in cells is provided that includes the step of contacting target cells either parenterally or directly into the tumor or tissue adjacent to the tumor cells with the nucleic acid of the present invention.

Antisense Guanidinium Peptide Nucleic Acid (Gpna) Oligonucleotides As Antitumor Agents

View page
US Patent:
7960360, Jun 14, 2011
Filed:
Nov 13, 2007
Appl. No.:
11/939018
Inventors:
Jennifer Rubin Grandis - Pittsburgh PA, US
Sufi Mary Thomas - Cheswick PA, US
Danith H. Ly - Pittsburgh PA, US
International Classification:
A01N 43/04
A61K 31/70
US Classification:
514 44
Abstract:
A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.

Stat3 Decoy Oligonucleotides And Uses Therefor

View page
US Patent:
20060293264, Dec 28, 2006
Filed:
Jul 22, 2005
Appl. No.:
11/188248
Inventors:
Jennifer Grandis - Pittsburgh PA, US
Daniel Johnson - Glenshaw PA, US
Paul Leong - Pittsburgh PA, US
International Classification:
A61K 48/00
A61K 33/36
A61K 31/7072
A61K 31/7048
A61K 31/704
A61K 31/525
A61K 31/675
A61K 31/66
A61K 31/337
US Classification:
514044000, 424649000, 514081000, 514700000, 514034000, 514049000, 514027000, 514109000, 514449000, 514283000, 424623000, 514410000, 514251000
Abstract:
A composition is provided that is useful in treating cancers in which STAT3 is activated, such as squamous cell carcinomas including squamous cell carcinoma of the head and neck. The composition comprises an effective amount of a STAT3 decoy and a pharmaceutically acceptable carrier. Also provided are methods of treating such cancers and methods of modulating STAT3 transcriptional activation in a cell.

Antisense Egfras Guanidinium Peptide Nucleic Acid (Gpna) Oligonucleotides As Antitumor Agents

View page
US Patent:
20110306562, Dec 15, 2011
Filed:
May 13, 2011
Appl. No.:
13/107344
Inventors:
Jennifer Rubin Grandis - Pittsburgh PA, US
Sufi Mary Thomas - Cheswick PA, US
Danith H. Ly - Pittsburgh PA, US
International Classification:
A61K 38/02
A61P 35/00
C07K 2/00
US Classification:
514 193, 530322
Abstract:
A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.

Stabilized Stat3 Decoy Oligonucleotides And Uses Therefor

View page
US Patent:
20120288536, Nov 15, 2012
Filed:
Jun 7, 2012
Appl. No.:
13/491343
Inventors:
Jennifer R. Grandis - Pittsburgh PA, US
Daniel Johnson - Glenshaw PA, US
Danith Ly - Pittsburgh PA, US
Assignee:
Carnegie Melton - Pittsburgh PA
University of Pittsburgh - Of The Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
C07H 21/00
A61K 9/00
A61N 5/10
C07H 21/04
A61P 35/00
A61P 35/02
A61K 31/713
A61K 39/395
US Classification:
424400, 536 231, 514 44 R, 4241331, 600 1
Abstract:
The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer.

Compositions And Methods Of Treating Head And Neck Cancer

View page
US Patent:
20130171124, Jul 4, 2013
Filed:
Jul 25, 2012
Appl. No.:
13/557988
Inventors:
Le Cong - Brookline MA, US
Ann Marie Egloff - Pittsburgh PA, US
Levi A. Garraway - Newton MA, US
Jennifer Rubin Grandis - Pittsburgh PA, US
Eric S. Lander - Cambridge MA, US
Nicholas Stransky - Boston MA, US
Aaron D. Tward - Boston MA, US
Feng Zhang - Cambridge MA, US
International Classification:
A61K 38/16
A61K 45/06
A61K 38/46
US Classification:
424 946, 514 193, 435375
Abstract:
The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.

Diagnostic Protocol

View page
US Patent:
6063586, May 16, 2000
Filed:
Feb 4, 1998
Appl. No.:
9/018796
Inventors:
Jennifer Rubin Grandis - Pittsburgh PA
Assignee:
Eye & Ear Foundation - Oakmont PA
International Classification:
A61K 39395
G01N 3353
US Classification:
435 723
Abstract:
A cancer prognostic having particular utility in the prognosis of head and neck squamous cell cancer, in which the expression levels of either or both of Transforming Growth Factor Alpha (TGF-. alpha. ) or Epidermal Growth Factor Receptor (EGFR) are assayed directly from a sample of tumor tissue. The expression level once quantitated is normalized as to standard, and the standardized expression level is compared to the prognostic threshold of about 83% of standard for TGF-. alpha. or of about 23% of standard for EGFR, or the corresponding upper threshold of the "low" tertile regardless of how calculated. Virtually all if not all patients demonstrating this low expression level survive at least five years after initial diagnosis, assuming completion of treatment with standard surgical tumor excision and radiation protocols for squamous cell head and neck cancer. Whether an individual patient's expression levels of TGF-. alpha. and EGFR fall inside or outside of this category signifies whether the patient is in a good or poor prognostic category, respectively, which in turn guides appropriate choice of therapy.

6-Aryl-7-Substituted-3-(1H-Pyrazol-5-Yl)-7H-[1,2,4]Triazolo[3,4-B][1,3,4]Thiadiazines As Inhibitors Of The Stat3 Pathway With Anti-Proliferative Activity

View page
US Patent:
20200339602, Oct 29, 2020
Filed:
Apr 10, 2020
Appl. No.:
16/846089
Inventors:
- Pittsburgh PA, US
Peter Wipf - Pittsburgh PA, US
Jennifer Rubin Grandis - Pittsburgh PA, US
Matthew G. LaPorte - Pittsburgh PA, US
Paul A. Johnston - Sewickley PA, US
Mark E. Schurdak - Pittsburgh PA, US
Raffaele Colombo - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
C07D 513/04
A61P 35/00
Abstract:
Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
Control profile
Jennifer R Grandis from San Francisco, CA, age ~63 Get Report